Pawel Chrom1, Rafal Stec2, Lubomir Bodnar2, Cezary Szczylik2. 1. Department of Oncology, Military Institute of Medicine, Warsaw, Poland pawel.chrom@gmail.com. 2. Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Abstract
AIM: The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. PATIENTS AND METHODS: Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). RESULTS: Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). CONCLUSION: The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease. Copyright
AIM: The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. PATIENTS AND METHODS: Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). RESULTS: Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). CONCLUSION: The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease. Copyright
Authors: Nirmish Singla; Zhiqun Xie; Ze Zhang; Ming Gao; Qurratulain Yousuf; Oreoluwa Onabolu; Tiffani McKenzie; Vanina Toffessi Tcheuyap; Yuanqing Ma; Jacob Choi; Renee McKay; Alana Christie; Oscar Reig Torras; Isaac A Bowman; Vitaly Margulis; Ivan Pedrosa; Christopher Przybycin; Tao Wang; Payal Kapur; Brian Rini; James Brugarolas Journal: JCI Insight Date: 2020-04-09
Authors: Karin Purshouse; Sarah Chamberlain; Maria Soares; Mark Tuthill; Andrew Protheroe; David R Mole Journal: BMC Cancer Date: 2019-10-17 Impact factor: 4.430